NDUFAF3
ENSG00000178057
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFAF3
- Gene name
- NADH:ubiquinone oxidoreductase complex assembly factor 3
- Gene symbol
- NDUFAF3
- Previous gene symbols
- C3orf60
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3
- MGC10527
- DKFZP564J0123
- E3-3
- 2P1
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial respiratory chain complex assembly factors
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 486.22
- Tissue specificity (Gini)
- 0.255
- Tissue specificity (tau)
- 0.873
- KEGG gene identifiers
- hsa:25915
- Reactome pathways
- R-HSA-6799198
- Protein interaction confidence
- 0.910705
- Protein interaction partners
- 61
- End position
- 49023495
- Start position
- 49020459
- Chromosome
- 3
- Strand
- Forward
- Nucleus . Mitochondrion inner membrane .
Publication evidence
- PubMed 19463981
- Tissue specificity (tau)
- 0.873392
- Expression inequality (Gini)
- 0.25541
Expression in transcripts per million
- Testis
- 486.22
- Pituitary
- 112.58
- Adrenal Gland
- 98.1
- Thyroid
- 95.16
- Brain - Spinal cord (cervical c-1)
- 91.9
Expression in transcripts per million
- Testis486.22
- Pituitary112.58
- Adrenal Gland98.1
- Thyroid95.16
- Brain - Spinal cord (cervical c-1)91.9
- Nerve - Tibial87.27
- Fallopian Tube84.51
- Cells - EBV-transformed lymphocytes84.24
- Cervix - Endocervix83.83
- Cells - Cultured fibroblasts83.04
- Cervix - Ectocervix81.53
- Uterus76.23
- Heart - Atrial Appendage73.81
- Ovary73.59
- Artery - Aorta71.3
- Adipose - Visceral (Omentum)70.13
- Prostate69.07
- Breast - Mammary Tissue67.97
- Artery - Coronary67.73
- Lung66.52
- Brain - Frontal Cortex (BA9)65.56
- Brain - Substantia nigra64.01
- Brain - Hypothalamus63.99
- Adipose - Subcutaneous62.76
- Bladder62.72
And 29 more, listed on the interactive page.
Biological processes
- GO:0032981
- GO:0005634
- GO:0005739
- GO:0005743
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor